Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $4,365,788.28 in Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $30.38, for a total value of $4,365,788.28. Following the completion of the sale, the insider directly owned 161,679 shares in the company, valued at $4,911,808.02. This represents a 47.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Tuesday, November 3rd, Corporate Gp Vi Ltd. Qiming sold 111,313 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.89, for a total value of $3,327,145.57.
• On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.84, for a total value of $1,310,871.20.
• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total value of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total value of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total transaction of $4,044,632.48.
• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total transaction of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total transaction of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total transaction of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total transaction of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.

Alamar Biosciences Trading Down 1.8%

ALMR opened at $26.91 on Friday. The firm has a market capitalization of $1.87 billion and a price-to-earnings ratio of -13.73. Alamar Biosciences, Inc. has a twelve month low of $18.84 and a twelve month high of $39.61. The stock’s 50-day simple moving average is $30.24. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. The business had revenue of $33.55 million for the quarter. As a group, analysts predict that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alamar Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Braidwell LP purchased a new stake in Alamar Biosciences in the second quarter valued at approximately $29,365,000. Wellington Management Group LLP acquired a new position in Alamar Biosciences during the second quarter worth $12,407,000. State Street Corp acquired a new position in Alamar Biosciences during the second quarter worth $3,930,000. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Alamar Biosciences by 18.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock worth $2,280,000 after buying an additional 10,461 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of Alamar Biosciences during the second quarter worth $283,000.

Analyst Ratings Changes

Several equities research analysts recently commented on ALMR shares. TD Cowen increased their price target on Alamar Biosciences from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus lifted their price objective on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings lowered Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Finally, JPMorgan Chase & Co. upped their target price on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Alamar Biosciences currently has a consensus rating of “Hold” and a consensus price target of $33.00.

Alamar Biosciences News Roundup

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68%, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. It also raised its 2026 revenue outlook to $121 million–$123 million, supporting its growth outlook. Q3 revenue and guidance
• Positive Sentiment: Alamar and GSK are collaborating on a large-scale proteomics study using Alamar’s platform. The research could increase the platform’s visibility, though no financial terms were disclosed. Alamar and GSK study
• Positive Sentiment: Analysts raised their price targets: TD Cowen lifted its target to $36 and maintained a Buy rating, while BofA Securities raised its target to $35 from $31. These moves indicate improved analyst expectations, though targets are not guarantees. TD Cowen price target BofA Securities price target
• Neutral Sentiment: The company plans to participate in upcoming investor conferences; the announcement did not include new financial guidance or other material business updates. Investor conferences announcement
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares on Nov. 3, after selling 43,930 shares on Nov. 2. The repeated sales—and the reduction in its reported ownership—could add supply and pressure sentiment; the filings do not give a reason for the sales. SEC filing on shareholder sale

About Alamar Biosciences

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.